NO2009027I1 - Arg34Lys26(N epsilon-(gamma-glutamyl(N alfa-heksadecanoyl))-GLP-1-(7-37) - Google Patents

Arg34Lys26(N epsilon-(gamma-glutamyl(N alfa-heksadecanoyl))-GLP-1-(7-37)

Info

Publication number: NO2009027I1
Authority: NO; Norway
Prior art keywords: glp; arg34lys26; hexadecanoyl; glutamyl; epsilon
Prior art date: 1996-08-30

Application number

NO2009027C

Other languages

English (en)

Other versions

NO2009027I2 (no

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

2009-11-18

Publication date

2009-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2009027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-18 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2009-11-30 Publication of NO2009027I1 publication Critical patent/NO2009027I1/no

2015-01-19 Publication of NO2009027I2 publication Critical patent/NO2009027I2/no

Links

101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 title abstract 2
-1 alpha-hexadecanoyl Chemical group 0.000 title 1
125000002642 gamma-glutamyl group Chemical group 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biophysics (AREA)
Child & Adolescent Psychology (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO2009027C 1996-08-30 2009-11-18 Arg34Lys26(N epsilon-(gamma-glutamyl(N alfa-heksadecanoyl))-GLP-1-(7-37) NO2009027I2 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DK93196		1996-08-30
DK125996		1996-11-08
DK147096		1996-12-20
PCT/DK1997/000340 WO1998008871A1 (en)	1996-08-30	1997-08-22	Glp-1 derivatives

Publications (2)

Publication Number	Publication Date
NO2009027I1 true NO2009027I1 (no)	2009-11-30
NO2009027I2 NO2009027I2 (no)	2015-01-19

Family

ID=27221005

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19990950A NO325273B1 (no)	1996-08-30	1999-02-26	GLP-1-derivater
NO2009027C NO2009027I2 (no)	1996-08-30	2009-11-18	Arg34Lys26(N epsilon-(gamma-glutamyl(N alfa-heksadecanoyl))-GLP-1-(7-37)
NO2019036C NO2019036I1 (no)	1996-08-30	2019-09-20	Liraglutid - forlenget SPC

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO19990950A NO325273B1 (no)	1996-08-30	1999-02-26	GLP-1-derivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2019036C NO2019036I1 (no)	1996-08-30	2019-09-20	Liraglutid - forlenget SPC

Country Status (21)

Country	Link
EP (2)	EP0944648B1 (no)
JP (3)	JP3149958B2 (no)
KR (1)	KR100556067B1 (no)
CN (1)	CN1271086C (no)
AT (1)	ATE356830T1 (no)
BR (1)	BRPI9711437B8 (no)
CA (2)	CA2468374C (no)
CZ (1)	CZ300837B6 (no)
DE (3)	DE69737479D1 (no)
DK (1)	DK0944648T3 (no)
ES (1)	ES2283025T3 (no)
FR (1)	FR09C0054I2 (no)
HU (1)	HU227021B1 (no)
IL (3)	IL128332A0 (no)
NL (1)	NL300422I2 (no)
NO (3)	NO325273B1 (no)
PL (1)	PL192359B1 (no)
PT (1)	PT944648E (no)
RU (1)	RU2214419C2 (no)
UA (1)	UA72181C2 (no)
WO (1)	WO1998008871A1 (no)

Families Citing this family (500)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2262647C (en)	1996-08-08	2007-12-04	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
ATE356830T1 (de) *	1996-08-30	2007-04-15	Novo Nordisk As	Glp-1 derivate
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
EP1056774A1 (en) *	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
EP1840134B1 (en) *	1998-02-27	2016-04-13	Novo Nordisk A/S	GLP-1 derivatives
EP1056775B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043707A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	N-terminally modified glp-1 derivatives
AU2610799A (en) *	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
JP2002512175A (ja)	1998-02-27	2002-04-23	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ−１類似体の誘導体類
EP1062229A1 (en)	1998-03-09	2000-12-27	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE251465T1 (de) *	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
US6720407B1 (en)	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
CZ2001690A3 (cs) *	1998-08-28	2002-04-17	Eli Lilly And Company	Způsob podávání inzulinotropních peptidů
EP1666054A1 (en) *	1998-08-28	2006-06-07	Eli Lilly & Company	Method for administering insulinotropic peptides
JP2002524514A (ja)	1998-09-17	2002-08-06	イーライ・リリー・アンド・カンパニー	タンパク質製剤
MY155270A (en) *	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
DK1137667T3 (da) *	1998-12-07	2005-02-14	Sod Conseils Rech Applic	GLP-1-analoger
CZ303399B6 (cs) *	1998-12-07	2012-08-29	Ipsen Pharma S.A.S.	Peptidový analog GLP-1 a farmaceutický prostredek jej obsahující
RU2288232C9 (ru)	1998-12-07	2007-04-20	Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас	Аналоги glp-1
AU777564B2 (en) *	1999-01-14	2004-10-21	Amylin Pharmaceuticals, Inc.	Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
ATE509028T1 (de)	1999-03-15	2011-05-15	Novo Nordisk As	Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
EP1956000B1 (en)	1999-03-17	2016-10-05	Novo Nordisk A/S	Acylating agents useful for acylating peptides
KR20020002480A (ko) *	1999-03-17	2002-01-09	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	펩티드의 아실화법 및 신규한 아실화제
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
AU775063C (en) *	1999-04-30	2005-05-12	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
EP1180121B9 (en)	1999-05-17	2004-09-08	Conjuchem, Inc.	Long lasting insulinotropic peptides
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
WO2001035988A1 (en) *	1999-11-12	2001-05-25	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en)	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
US6844321B2 (en) *	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
ES2253353T3 (es)	2000-03-08	2006-06-01	Novo Nordisk A/S	Reduccion del colesterol serico.
DE10013895A1 (de)	2000-03-21	2001-10-04	Dmc2 Degussa Metals Catalysts Cerdec Ag	Verfahren zur katalytischen Umsetzung von Kohlenmonoxid in einem Wasserstoff enthaltenden Gasgemisch
AU2001279526A1 (en) *	2000-08-02	2002-02-13	Theratechnologies Inc.	Modified peptides with increased potency
US7090869B2 (en)	2000-12-01	2006-08-15	Takeda Pharmaceutical Company Limited	Method for producing preparation containing bioactive substance
HU229218B1 (en) *	2000-12-07	2013-09-30	Lilly Co Eli	Glp-1 fusion proteins
KR20030063462A (ko)	2000-12-21	2003-07-28	아벤티스 파마 도이칠란트 게엠베하	디페닐 아제티디논 유도체, 이의 제조 방법, 이들화합물을 함유하는 약제 및 이의 용도
DE50111751D1 (de)	2000-12-21	2007-02-08	Sanofi Aventis Deutschland	Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
JP2004518756A (ja)	2001-03-07	2004-06-24	ノボ　ノルディスク　アクティーゼルスカブ	Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE10142660A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
EP1698636A1 (en) *	2001-05-02	2006-09-06	Novo Nordisk A/S	Preparation of derivatized peptides from bile acids
US6653492B2 (en)	2001-05-02	2003-11-25	Novo Nordick A/S	Preparation of bile acids
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
JP5562510B2 (ja)	2001-06-28	2014-07-30	ノヴォノルディスクアー／エス	修飾ｇｌｐ−１の安定な処方剤
US7595172B2 (en)	2001-07-24	2009-09-29	Novo Nordisk A/S	Method for making acylated polypeptides
US20030082671A1 (en)	2001-07-24	2003-05-01	Thomas Hoeg-Jensen	Method for making acylated polypeptides
NZ531293A (en)	2001-08-22	2005-08-26	Aventis Pharma Gmbh	Pharamceuticals containing 1,4-benzothiepine-1,1-dioxide derivatives and another active substances such as ezetimibe, pamaqueside or tiqueside for treating lipid metabolism and atherosclerotic disorders
DE10142659A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142661B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
AU2002333456B2 (en)	2001-08-31	2008-07-17	Sanofi-Aventis Deutschland Gmbh	Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
DE10142662B4 (de)	2001-08-31	2004-07-08	Aventis Pharma Deutschland Gmbh	Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142722A1 (de)	2001-08-31	2003-03-27	Aventis Pharma Deutschland GmbH, 65929 Frankfurt	C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7399777B2 (en)	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
US6884812B2 (en)	2001-08-31	2005-04-26	Aventis Pharma Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10142667B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142666A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142665B4 (de)	2001-08-31	2004-05-06	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-one und ihre Derivate
DE10142663B4 (de)	2001-08-31	2004-08-19	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-ol-Systeme
DE10142668A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DK1499277T3 (da)	2001-09-24	2009-05-11	Imp Innovations Ltd	PYY-36 til reduktion eller forebyggelse af obesitet
EP2243776A1 (en)	2001-10-12	2010-10-27	High Point Pharmaceuticals, LLC	Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
IL160917A0 (en) *	2001-10-18	2004-08-31	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
IL162620A0 (en)	2001-12-21	2005-11-20	Novo Nordisk As	Amide derivatives as gk activators
JP2005518408A (ja)	2001-12-29	2005-06-23	ノボ　ノルディスク　アクティーゼルスカブ	異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
AR038102A1 (es) *	2002-01-08	2004-12-29	Lilly Co Eli	Analogos extendidos de peptido 1 de tipo glucagon
EP1474163A2 (en) *	2002-01-10	2004-11-10	Imperial College Innovations Limited	Modification of feeding behavior
US8058233B2 (en)	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
WO2003072195A2 (en)	2002-02-20	2003-09-04	Eli Lilly And Company	Method for administering glp-1 molecules
US7223796B2 (en)	2002-04-11	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en)	2002-06-07	2006-05-23	Aventis Pharma Deutschland Gmbh	N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7176193B2 (en)	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en)	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en)	2002-06-19	2010-03-02	Sanofi-Aventis Deutschland Gmbh	Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
EP1531815B1 (en)	2002-06-27	2014-09-24	Novo Nordisk A/S	Glucokinase activators
ATE432289T1 (de) *	2002-07-04	2009-06-15	Zealand Pharma As	Glp-1 und behandlungsmethode für diabetes
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7262220B2 (en)	2002-07-11	2007-08-28	Sanofi-Aventis Deutschland Gmbh	Urea- and urethane-substituted acylureas, process for their preparation and their use
PL373329A1 (en)	2002-07-12	2005-08-22	Sanofi-Aventis Deutschland Gmbh	Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US7141561B2 (en)	2002-07-25	2006-11-28	Sanofi-Aventis Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US8821915B2 (en)	2002-08-09	2014-09-02	Veroscience, Llc	Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
PL210455B1 (pl) *	2002-09-25	2012-01-31	Novo Nordisk As	Sposób otrzymywania acylowanych peptydów
AU2003271452A1 (en)	2002-09-25	2004-04-19	Theratechnologies Inc.	Modified glp-1 peptides with increased biological potency
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
US20040157922A1 (en)	2002-10-04	2004-08-12	Aventis Pharma Deutschland Gmbh	Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en)	2002-10-12	2007-04-24	Sanofi-Aventis Deutschland Gmbh	Bicyclic inhibitors of hormone sensitive lipase
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7655618B2 (en)	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en)	2002-12-27	2008-01-01	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US20040242583A1 (en)	2003-01-20	2004-12-02	Aventis Pharma Deutschland Gmbh	Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en)	2003-01-23	2007-02-20	Sanofi-Aventis Deutschland Gmbh	Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE602004031927D1 (de)	2003-02-04	2011-05-05	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
US7652007B2 (en)	2003-02-13	2010-01-26	Sanofi-Aventis Deutschland Gmbh	Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
US7390814B2 (en)	2003-02-13	2008-06-24	Sanofi-Aventis Deutschland Gmbh	Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
DE10306250A1 (de)	2003-02-14	2004-09-09	Aventis Pharma Deutschland Gmbh	Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7501440B2 (en)	2003-03-07	2009-03-10	Sanofi-Aventis Deutschland Gmbh	Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
WO2004078195A1 (ja)	2003-03-07	2004-09-16	Ajinomoto Co., Inc.	腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
AU2004231461B2 (en)	2003-03-19	2009-11-12	Eli Lilly And Company	Polyethelene glycol linked GLP-1 compounds
EP2256189A1 (en)	2003-03-28	2010-12-01	National Institute Of Agrobiological Sciences	Process for producing a plant storage organ in which a GLP-1 derivative recombinant protein is highly produced.
DE10314610A1 (de)	2003-04-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
EP1787982B1 (en)	2003-04-11	2010-05-12	High Point Pharmaceuticals, LLC	11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
AU2004232858B2 (en)	2003-04-23	2009-07-09	Mannkind Corporation	Hydraulically actuated pump for long duration medicament administration
CN102940879B (zh)	2003-06-03	2017-06-06	诺沃挪第克公司	稳定化的药物肽组合物
JP2007524592A (ja)	2003-06-03	2007-08-30	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
DE602004023626D1 (de)	2003-08-21	2009-11-26	Novo Nordisk As	Trennung von polypeptiden mit einer racemisierten aminosäure
WO2005023291A2 (en) *	2003-09-11	2005-03-17	Novo Nordisk A/S	Use of glp1-agonists in the treatment of patients with type i diabetes
RU2401276C2 (ru) *	2003-09-19	2010-10-10	Ново Нордиск А/С	Производные глюкагон-подобного пептида-1 (glp-1)
CN101380476A (zh) *	2003-09-19	2009-03-11	诺沃挪第克公司	治疗肽的清蛋白结合型衍生物
ATE525083T1 (de) *	2003-11-13	2011-10-15	Novo Nordisk As	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
PL3300721T3 (pl)	2003-11-20	2019-08-30	Novo Nordisk A/S	Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
ATE498404T1 (de)	2003-12-09	2011-03-15	Novo Nordisk As	Regulierung der nahrungspräferenz mit glp-1- agonisten
EP1711523B1 (en) *	2003-12-16	2012-10-10	Ipsen Pharma	Analogues of glp-1
JP2007514752A (ja)	2003-12-16	2007-06-07	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１医薬組成物
ATE461217T1 (de)	2003-12-18	2010-04-15	Novo Nordisk As	Glp-1-verbindungen
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
EP2444397A1 (en)	2004-01-06	2012-04-25	Novo Nordisk A/S	Heteroaryl-ureas and their use as glucokinase activators
BRPI0506694A (pt) *	2004-01-08	2007-05-02	Theratechnologies Inc	análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
EP2033662B1 (en)	2004-01-21	2012-10-17	Novo Nordisk Health Care AG	Transglutaminase mediated conjugation of peptides
US7241787B2 (en)	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7470706B2 (en)	2004-01-31	2008-12-30	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en)	2004-01-31	2008-07-22	Sanofi-Aventis Deutschland Gmbh,	7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en)	2004-01-31	2009-03-03	Sanofi Aventis Deutschland Gmbh	Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de)	2004-02-02	2005-08-18	Aventis Pharma Deutschland Gmbh	Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
KR100564618B1 (ko)	2004-03-11	2006-03-28	삼성전자주식회사	디스크 드라이브의 층간 탐색 방법
GT200500063A (es)	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
DE602004004631D1 (de)	2004-04-01	2007-03-22	Sanofi Aventis Deutschland	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
EP1604988A1 (en)	2004-05-18	2005-12-14	Sanofi-Aventis Deutschland GmbH	Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
US8410047B2 (en)	2004-06-11	2013-04-02	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
WO2006014425A1 (en)	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
ES2442223T3 (es)	2004-08-31	2014-02-10	Novo Nordisk A/S	Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
EP1841749A1 (en)	2004-09-02	2007-10-10	Metabasis Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
JP5107713B2 (ja)	2004-10-07	2012-12-26	ノヴォノルディスクアー／エス	遅延性のエキセンディン−４化合物
EP1799710A2 (en)	2004-10-07	2007-06-27	Novo Nordisk A/S	Protracted glp-1 compounds
WO2006051110A2 (en)	2004-11-12	2006-05-18	Novo Nordisk A/S	Stable formulations of insulinoptropic peptides
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
CA2590720A1 (en)	2004-12-03	2006-06-08	Lone Jeppesen	Heteroaromatic glucokinase activators
TWI376234B (en)	2005-02-01	2012-11-11	Msd Oss Bv	Conjugates of a polypeptide and an oligosaccharide
EP2256130B1 (en)	2005-02-02	2013-09-25	Novo Nordisk A/S	Novel insulin derivatives
US20080171695A1 (en)	2005-02-02	2008-07-17	Novo Nordisk A/S	Insulin Derivatives
JP5755398B2 (ja)	2005-03-18	2015-07-29	ノヴォノルディスクアー／エス	伸長されたｇｌｐ−１化合物
TWI372629B (en)	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
US7955305B2 (en)	2005-05-06	2011-06-07	Medtronic Minimed, Inc.	Needle inserter and method for infusion device
US8137314B2 (en)	2006-08-23	2012-03-20	Medtronic Minimed, Inc.	Infusion medium delivery device and method with compressible or curved reservoir or conduit
US20080097291A1 (en)	2006-08-23	2008-04-24	Hanson Ian B	Infusion pumps and methods and delivery devices and methods with same
US8512288B2 (en)	2006-08-23	2013-08-20	Medtronic Minimed, Inc.	Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8277415B2 (en)	2006-08-23	2012-10-02	Medtronic Minimed, Inc.	Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8840586B2 (en)	2006-08-23	2014-09-23	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
US7905868B2 (en)	2006-08-23	2011-03-15	Medtronic Minimed, Inc.	Infusion medium delivery device and method with drive device for driving plunger in reservoir
WO2006126673A1 (ja) *	2005-05-27	2006-11-30	Daiichi Sankyo Company, Limited	組み合わせによる糖尿病治療薬
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
ES2449618T3 (es)	2005-06-30	2014-03-20	High Point Pharmaceuticals, Llc	Ácidos fenoxiacéticos como activadores de PPAR-delta
ES2375929T3 (es)	2005-07-04	2012-03-07	High Point Pharmaceuticals, Llc	Antagonistas del receptor histamina h3.
CA2615938C (en)	2005-07-14	2014-04-29	Novo-Nordisk A/S	Urea glucokinase activators
WO2007015805A1 (en)	2005-07-20	2007-02-08	Eli Lilly And Company	1-amino linked compounds
SI1767545T1 (sl)	2005-09-22	2010-03-31	Biocompatibles Uk Ltd	GLP Glukagonu podobni peptidi fuzijski polipeptidi s povečano rezistenco na peptidazo
US8496646B2 (en)	2007-02-09	2013-07-30	Deka Products Limited Partnership	Infusion pump assembly
PT1951658E (pt)	2005-11-17	2012-11-12	Lilly Co Eli	Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
EP1968644B1 (en) *	2005-12-16	2012-06-27	Nektar Therapeutics	Polymer conjugates of glp-1
EA201101085A1 (ru)	2005-12-22	2012-05-30	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Феноксиуксусные кислоты в качестве активаторов ppar дельта
SI1984009T1 (sl)	2006-01-18	2013-02-28	Qps, Llc	Farmacevtski sestavki z izboljĺ ano stabilnostjo
US11364335B2 (en)	2006-02-09	2022-06-21	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
US11497846B2 (en)	2006-02-09	2022-11-15	Deka Products Limited Partnership	Patch-sized fluid delivery systems and methods
US11027058B2 (en)	2006-02-09	2021-06-08	Deka Products Limited Partnership	Infusion pump assembly
US9492606B2 (en)	2006-02-09	2016-11-15	Deka Products Limited Partnership	Apparatus, system and methods for an infusion pump assembly
US12070574B2 (en)	2006-02-09	2024-08-27	Deka Products Limited Partnership	Apparatus, systems and methods for an infusion pump assembly
US12151080B2 (en)	2006-02-09	2024-11-26	Deka Products Limited Partnership	Adhesive and peripheral systems and methods for medical devices
US11478623B2 (en)	2006-02-09	2022-10-25	Deka Products Limited Partnership	Infusion pump assembly
BRPI0707576A2 (pt)	2006-02-09	2011-05-10	Deka Products Lp	sistemas de envio de fluido por bombeamento e mÉtodos de uso do conjunto de aplicaÇço de forÇa
US12274857B2 (en)	2006-02-09	2025-04-15	Deka Products Limited Partnership	Method and system for shape-memory alloy wire control
KR101419554B1 (ko)	2006-03-13	2014-07-17	교린 세이야꾸 가부시키 가이샤	Ｇｓｋ３ 억제제로서 아미노퀴놀론
US20090054305A1 (en)	2006-03-15	2009-02-26	Novo Nordisk A/S	Mixtures of Amylin and Insulin
ES2388681T3 (es)	2006-03-28	2012-10-17	High Point Pharmaceuticals, Llc	Benzotiazoles con actividad de los receptores de histamina H3
EP2982399B1 (en)	2006-03-30	2017-12-06	Valeritas, Inc.	Multi-cartridge fluid delivery device
SI2049475T1 (sl)	2006-04-24	2012-04-30	Lilly Co Eli	Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
ATE444741T1 (de)	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
CA2659570C (en)	2006-05-29	2015-10-06	High Point Pharmaceuticals, Llc	3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
JP5231412B2 (ja)	2006-07-11	2013-07-10	キューピーエスリミテッドライアビリティカンパニー	ペプチドを持続的放出により送達するための薬理組成物
TW200821386A (en)	2006-07-18	2008-05-16	Centocor Inc	Human GLP-1 mimetibodies, compositions, methods and uses
KR20090047458A (ko)	2006-08-08	2009-05-12	사노피-아벤티스	아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
US7828764B2 (en)	2006-08-23	2010-11-09	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
US7811262B2 (en)	2006-08-23	2010-10-12	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
US7789857B2 (en)	2006-08-23	2010-09-07	Medtronic Minimed, Inc.	Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7794434B2 (en)	2006-08-23	2010-09-14	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
ES2531934T3 (es)	2006-09-01	2015-03-20	Novo Nordisk Health Care Ag	Glicoproteínas modificadas
UA100497C2 (ru)	2006-09-07	2013-01-10	Никомед Гмбх	Комбинированное лечение сахарного диабета
CA2669874A1 (en)	2006-11-15	2008-05-22	High Point Pharmaceuticals, Llc	Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
US8318778B2 (en)	2007-01-11	2012-11-27	Novo Nordisk A/S	Urea glucokinase activators
DE102007002260A1 (de)	2007-01-16	2008-07-31	Sanofi-Aventis	Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008098246A1 (en)	2007-02-09	2008-08-14	Deka Products Limited Partnership	Automated insertion assembly
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
EP1975176A1 (en) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Novel glp-1 fusion peptides, their production and use
US7959715B2 (en)	2007-04-30	2011-06-14	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir air bubble management
CA2685474C (en)	2007-04-30	2014-07-08	Medtronic Minimed, Inc.	Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
US7963954B2 (en)	2007-04-30	2011-06-21	Medtronic Minimed, Inc.	Automated filling systems and methods
US8613725B2 (en)	2007-04-30	2013-12-24	Medtronic Minimed, Inc.	Reservoir systems and methods
US8434528B2 (en)	2007-04-30	2013-05-07	Medtronic Minimed, Inc.	Systems and methods for reservoir filling
US8323250B2 (en)	2007-04-30	2012-12-04	Medtronic Minimed, Inc.	Adhesive patch systems and methods
US8597243B2 (en)	2007-04-30	2013-12-03	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir air bubble management
JP5508258B2 (ja)	2007-06-04	2014-05-28	ベングリオンユニバーシティオブザネガフリサーチアンドディベロップメントオーソリティ	トリアリール化合物および前記化合物を含む組成物
US20080319221A1 (en)	2007-06-22	2008-12-25	Bernd Junker	Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
JP2009019027A (ja) *	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US20100216691A1 (en)	2007-07-16	2010-08-26	Novo Nordisk A/S	Protease Stabilized, Pegylated Insulin Analogues
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2190873B1 (en)	2007-09-05	2015-07-22	Novo Nordisk A/S	Truncated glp-1 derivatives and their therapeutical use
JP5476304B2 (ja)	2007-09-05	2014-04-23	ノボ・ノルデイスク・エー／エス	グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
EP2190460B1 (en)	2007-09-05	2014-12-17	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
ATE531721T1 (de)	2007-09-11	2011-11-15	Kyorin Seiyaku Kk	Cyanoaminochinolone als gsk-3-inhibitoren
CA2699152C (en)	2007-09-12	2015-11-24	Activx Biosciences, Inc.	Spirocyclic aminoquinolones as gsk-3 inhibitors
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
PL2209800T3 (pl)	2007-11-16	2013-12-31	Novo Nordisk As	Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
US20100317057A1 (en)	2007-12-28	2010-12-16	Novo Nordisk A/S	Semi-recombinant preparation of glp-1 analogues
US9526830B2 (en)	2007-12-31	2016-12-27	Deka Products Limited Partnership	Wearable pump assembly
US8881774B2 (en)	2007-12-31	2014-11-11	Deka Research & Development Corp.	Apparatus, system and method for fluid delivery
US8900188B2 (en)	2007-12-31	2014-12-02	Deka Products Limited Partnership	Split ring resonator antenna adapted for use in wirelessly controlled medical device
US9456955B2 (en)	2007-12-31	2016-10-04	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
US10188787B2 (en)	2007-12-31	2019-01-29	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
US10080704B2 (en)	2007-12-31	2018-09-25	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970476B (zh)	2008-01-09	2014-08-27	塞诺菲-安万特德国有限公司	具有超延迟时效特征的胰岛素衍生物
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
EP2259791A2 (en) *	2008-03-05	2010-12-15	Tel HaShomer Medical Research Infrastructure and Services Ltd.	Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
EP2254906B1 (en)	2008-03-18	2016-10-05	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
CN101555214B (zh)	2008-04-08	2012-07-11	北京嘉事联博医药科技有限公司	苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
WO2009158704A2 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR20110039348A (ko)	2008-08-06	2011-04-15	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
CN102149411A (zh)	2008-09-12	2011-08-10	诺沃—诺迪斯克有限公司	酰化肽或蛋白的方法
EP3881874A1 (en)	2008-09-15	2021-09-22	DEKA Products Limited Partnership	Systems and methods for fluid delivery
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
CA3016451A1 (en)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Combination of an insulin and a glp-1 agonist
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
ES2614427T3 (es)	2008-11-07	2017-05-31	The General Hospital Corporation	Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
IT1392655B1 (it)	2008-11-20	2012-03-16	Bio Ker S R L	Site-specific monoconjugated insulinotropic glp-1 peptides.
JP2012509879A (ja)	2008-11-21	2012-04-26	ハイポイントファーマシューティカルズ，リミティドライアビリティカンパニー	アダマンチルベンズアミド化合物
CA2745524C (en)	2008-12-05	2020-06-09	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
CA2747197A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
BRPI0823378A2 (pt)	2008-12-15	2019-09-24	Zealand Pharma As	análogos de glucagon
MX2011006320A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
JP5816097B2 (ja)	2009-01-22	2015-11-18	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
CA2748593A1 (en)	2009-01-23	2010-07-29	Novo Nordisk A/S	Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
CN101824087A (zh) *	2009-03-05	2010-09-08	连云港恒邦医药科技有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
JP5502889B2 (ja)	2009-03-11	2014-05-28	杏林製薬株式会社	ｇｓｋ−３阻害剤としての７−シクロアルキルアミノキノロン
CN102458376A (zh) *	2009-06-05	2012-05-16	Vero科学有限责任公司	多巴胺激动剂加上第一时相胰岛素促分泌剂的组合物用于治疗代谢失调
US9352025B2 (en)	2009-06-05	2016-05-31	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2014265118B2 (en) *	2009-06-05	2016-11-17	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US20120172298A1 (en) *	2009-06-11	2012-07-05	Novo Nordisk A/S	Glp-1 and fgf21 combinations for treatment of diabetes type 2
SI2454282T1 (sl)	2009-07-13	2015-06-30	Zealand Pharma A/S	Acilirani glukagonski analogi
US8614182B2 (en)	2009-07-30	2013-12-24	Jiangsu Hansoh Pharmaceuticals Co., Ltd.	GLP-1 analogues and their pharmaceutical salts and uses
CN101987868B (zh)	2009-07-30	2013-09-04	江苏豪森医药集团有限公司	Glp-1类似物的衍生物或其可药用盐和用途
CN105963710A (zh)	2009-08-06	2016-09-28	诺沃—诺迪斯克保健股份有限公司	具有延长的体内功效的生长激素
JP2013503135A (ja)	2009-08-26	2013-01-31	サノフイ	新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
RU2012117560A (ru)	2009-10-02	2013-11-10	Санофи	Применение соединений с активностью ингибиторов sglt-1/sglt-2 для получения лекарственных средств для лечения заболеваний костей
EP2491054A2 (en)	2009-10-22	2012-08-29	Cadila Healthcare Limited	Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
AR080669A1 (es)	2009-11-13	2012-05-02	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
EP2498801B1 (de)	2009-11-13	2018-01-24	Sanofi-Aventis Deutschland GmbH	HARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND desPro36Exendin-4(1-39)-Lys6-NH2 UND METHIONIN
PL2513140T3 (pl)	2009-12-16	2016-04-29	Novo Nordisk As	Podwójnie acylowane pochodne glp-1
EP2525848B1 (en)	2010-01-22	2016-08-03	DEKA Products Limited Partnership	System for shape-memory alloy wire control
BR112012018162A2 (pt)	2010-01-22	2017-10-03	Novo Nordisk Healthcare Ag	Compostos de hormônio do crescimento estáveis
SI2525834T1 (sl)	2010-01-22	2019-10-30	Novo Nordisk Healthcare Ag	Rastni hormoni s podaljšano in vivo učinkovitostjo
US20130012432A1 (en)	2010-02-26	2013-01-10	Novo Nordisk A/S	Peptides for Treatment of Obesity
BR112012021231A2 (pt)	2010-02-26	2015-09-08	Basf Plant Science Co Gmbh	método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
CN102770440A (zh) *	2010-03-01	2012-11-07	诺沃—诺迪斯克有限公司	纯化肽的制备性rp-hplc方法
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MX336412B (es)	2010-03-26	2016-01-19	Novo Nordisk As	Nuevos analogos de glucagon.
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR081339A1 (es)	2010-04-27	2012-08-08	Zealand Pharma As	Conjugados peptidicos
CA2793715A1 (en)	2010-04-30	2011-11-03	Sanwa Kagaku Kenkyusho Co., Ltd.	Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
US9169310B2 (en)	2010-06-24	2015-10-27	Zealand Pharma A/S	Glucagon analogues
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012028172A1 (en)	2010-08-30	2012-03-08	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
WO2012061466A2 (en)	2010-11-02	2012-05-10	The General Hospital Corporation	Methods for treating steatotic disease
CN103209711B (zh)	2010-11-09	2016-04-13	诺沃—诺迪斯克有限公司	双-酰化的glp-1衍生物
HUE036066T2 (hu)	2010-12-16	2018-06-28	Novo Nordisk As	GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
US20140045754A1 (en)	2011-01-19	2014-02-13	Joern Drustrup	Glp-1 compositions
WO2012098188A1 (en)	2011-01-19	2012-07-26	Novo Nordisk A/S	Glp-1 particles and compositions
JP2014504597A (ja)	2011-01-20	2014-02-24	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体とインスリン類似体の組合せ物
US10130684B2 (en)	2011-02-03	2018-11-20	Pharmedica Ltd.	Oral dissolving films for insulin administration, for treating diabetes
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de)	2011-03-08	2015-02-18	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
KR20140020292A (ko)	2011-03-28	2014-02-18	노보 노르디스크 에이/에스	신규 글루카곤 유사체
CN106117344B (zh)	2011-04-12	2020-11-03	诺沃—诺迪斯克有限公司	双酰化glp-1衍生物
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en)	2011-05-10	2014-03-19	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729157B1 (en)	2011-07-06	2019-01-16	The General Hospital Corporation	A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013029279A1 (zh) *	2011-09-03	2013-03-07	深圳市健元医药科技有限公司	新的glp-ⅰ类似物及其制备方法和用途
EP2753642B8 (en)	2011-09-06	2017-12-13	Novo Nordisk A/S	Glp-1 derivatives
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI596110B (zh)	2011-09-23	2017-08-21	諾佛儂迪克股份有限公司	新穎升糖素類似物
US9458214B2 (en)	2011-09-26	2016-10-04	Novartis Ag	Dual function fibroblast growth factor 21 proteins
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SI2763690T1 (sl)	2011-10-04	2016-03-31	Sanofi-Aventis Deutschland Gmbh	Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke
WO2013050378A1 (en)	2011-10-04	2013-04-11	Sanofi-Aventis Deutschland Gmbh	Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
CA2853884A1 (en)	2011-11-03	2013-05-10	Zealand Pharma A/S	Glp-1 receptor agonist peptide gastrin conjugates
EP2788027A2 (en)	2011-12-09	2014-10-15	Novo Nordisk A/S	Glp-1 agonists
AU2012360998B2 (en)	2011-12-29	2017-11-23	Novo Nordisk A/S	Dipeptide comprising a non-proteogenic amino acid
LT2814844T (lt)	2012-02-15	2017-10-25	Novo Nordisk A/S	Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9663568B2 (en)	2012-02-15	2017-05-30	Novo Nordisk A/S	Antibodies that bind peptidoglycan recognition protein 1
US11524151B2 (en)	2012-03-07	2022-12-13	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
RU2641198C3 (ru)	2012-03-22	2021-12-10	Ново Нордиск А/С	Композиции glp-1 пептидов и их получение
EP4331667A3 (en)	2012-03-22	2024-05-08	Novo Nordisk A/S	Compositions comprising a delivery agent and preparation thereof
HK1208232A1 (en)	2012-05-03	2016-02-26	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EP2844670B1 (en)	2012-05-03	2017-12-06	Zealand Pharma A/S	Glucagon-like-peptide-2 (glp-2) analogues
EP2846823B1 (en)	2012-05-08	2019-12-04	Novo Nordisk A/S	Double-acylated glp-1 derivatives
EP2846824B1 (en) *	2012-05-08	2017-04-05	Novo Nordisk A/S	Double-acylated glp-1 derivatives
EP2664374A1 (en) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
ES2871328T3 (es)	2012-06-20	2021-10-28	Novo Nordisk As	Formulación de comprimido que comprende un péptido y un agente de suministro
RU2018117557A (ru)	2012-07-01	2019-03-22	Ново Нордиск А/С	Применение долгодействующих пептидов glp-1
EP2873422A4 (en)	2012-07-10	2015-12-30	Takeda Pharmaceutical	PHARMACEUTICAL PREPARATION FOR INJECTION
PL2875043T3 (pl)	2012-07-23	2017-06-30	Zealand Pharma A/S	Analogi glukagonu
FR2994848B1 (fr)	2012-08-30	2014-08-22	Univ Paris Curie	Traitement de l'arthrose par les hormones incretines ou leurs analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2908844A1 (en)	2012-10-17	2015-08-26	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
IN2015DN03795A (no)	2012-10-24	2015-10-02	Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2014093696A2 (en)	2012-12-12	2014-06-19	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
CN104902920A (zh)	2012-12-21	2015-09-09	赛诺菲	作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CN103059127B (zh) *	2013-01-07	2014-12-17	天津嘉宏科技有限公司	Glp-1类似物及其制备方法与应用
EP2968471B1 (en)	2013-03-01	2017-07-19	Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca	Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
SG10201707622XA (en)	2013-03-15	2017-11-29	Protagonist Therapeutics Inc	Hepcidin analogues and uses therof
JP6464145B2 (ja)	2013-04-05	2019-02-06	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	成長ホルモン化合物製剤
MX362275B (es)	2013-04-18	2019-01-10	Novo Nordisk As	Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
HRP20181393T1 (hr)	2013-05-02	2018-11-02	Novo Nordisk A/S	Oralno doziranje spojeva glp-1
CA3130345A1 (en)	2013-07-03	2015-01-08	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
JP6599863B2 (ja) *	2013-08-15	2019-10-30	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
CA2926314C (en)	2013-10-17	2023-08-29	Zealand Pharma A/S	Acylated glucagon analogues
CR20160207A (es)	2013-11-05	2016-08-10	Ben Gurion Univ Of The Negev Res And Dev Authority	Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
MX369770B (es)	2013-11-06	2019-11-21	Zealand Pharma As	Compuestos agonistas triples de glucagón-glp-1-gip.
BR112016009889B1 (pt)	2013-11-06	2023-11-28	Zealand Pharma A/S	Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
CN103884846B (zh) *	2014-03-06	2016-06-08	杭州九源基因工程有限公司	一种利拉鲁肽生物学活性的检测方法
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10689429B2 (en)	2014-04-07	2020-06-23	Novo Nordisk A/S	Double-acylated GLP-1 compounds
RS60316B1 (sr)	2014-05-07	2020-07-31	Novo Nordisk As	Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21
SG11201609614QA (en)	2014-05-16	2016-12-29	Protagonist Therapeutics Inc	α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
WO2015185640A1 (en)	2014-06-04	2015-12-10	Novo Nordisk A/S	Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104987383A (zh) *	2014-07-08	2015-10-21	四川百利药业有限责任公司	一种glp-1衍生物
GB2528436A (en)	2014-07-15	2016-01-27	Lancaster Univ Business Entpr Ltd	Treatment of neurological diseases
SG11201700250WA (en)	2014-07-17	2017-02-27	Novo Nordisk As	Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
SG11201700327WA (en)	2014-07-17	2017-02-27	Protagonist Therapeutics Inc	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PL3189072T3 (pl)	2014-09-05	2019-04-30	Univ Copenhagen	Analogi peptydowe gip
EP3200812B8 (en)	2014-10-01	2021-04-28	Protagonist Therapeutics, Inc.	Novel alpha4beta7 peptide monomer and dimer antagonists
US10301371B2 (en)	2014-10-01	2019-05-28	Protagonist Therapeutics, Inc.	Cyclic monomer and dimer peptides having integrin antagonist activity
DK3006045T3 (en)	2014-10-07	2017-07-17	Cyprumed Gmbh	Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2016066744A2 (en)	2014-10-29	2016-05-06	Zealand Pharma A/S	Gip agonist compounds and methods
EP3226906B1 (en) *	2014-11-27	2019-06-12	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
PE20171622A1 (es)	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	Formulacion de relacion fija de insulina glargina/lixisenatida
TWI708781B (zh)	2014-12-23	2020-11-01	丹麥商諾佛儂迪克股份有限公司	Fgf21衍生物及其用途
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
AR103954A1 (es)	2015-03-18	2017-06-14	Zealand Pharma As	Análogos de amilina
US10426818B2 (en)	2015-03-24	2019-10-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Method and pharmaceutical composition for use in the treatment of diabetes
RU2735762C2 (ru)	2015-04-16	2020-11-06	Зилэнд Фарма А/С	Ацилированный аналог глюкагона, его применение и способы получения
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3359181A1 (en)	2015-10-07	2018-08-15	Cyprumed GmbH	Pharmaceutical formulations for the oral delivery of peptide drugs
US20190002503A1 (en)	2015-12-30	2019-01-03	Protagonist Therapeutics, Inc.	Analogues of hepcidin mimetics with improved in vivo half lives
EP3196206A1 (en)	2016-01-20	2017-07-26	Lonza Ltd	Method for preparation of liraglutide
EP3205660A1 (en)	2016-02-10	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Method for preparation of peptides with pswang linker
EP3405476B1 (en)	2016-01-20	2022-05-18	Polypeptide Laboratories Holding (PPL) AB	METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3205664A1 (en)	2016-02-11	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Method for preparation of liraglutide using bal linker
JP7053480B2 (ja)	2016-03-03	2022-04-12	ノヴォノルディスクアー／エス	Ｇｌｐ－１誘導体及びその使用
WO2017149109A1 (en)	2016-03-04	2017-09-08	Novo Nordisk A/S	Liraglutide in diabetic foot ulcer
MA43684A (fr)	2016-03-04	2018-11-28	Novo Nordisk As	Liraglutide utilisé dans le traitement de maladies rénales
CN109195618A (zh)	2016-03-23	2019-01-11	领导医疗有限公司	用于合成α4β7肽拮抗剂的方法
US11117946B2 (en)	2016-03-23	2021-09-14	Bachem Holding Ag	Method for preparing glucagon-like peptides
CA3018627A1 (en)	2016-03-23	2017-09-28	Bachem Holding Ag	Purification of glucagon-like peptide 1 analogs
TWI784968B (zh)	2016-09-09	2022-12-01	丹麥商西蘭製藥公司	澱粉素類似物
WO2018057977A1 (en)	2016-09-23	2018-03-29	Delpor, Inc.	Stable compositions for incretin mimetic compounds
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
JP2019535791A (ja)	2016-11-28	2019-12-12	ノヴォノルディスクアー／エス	血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
MA46897A (fr)	2016-11-28	2021-04-28	Novo Nordisk As	Insuline dégludec utilisée dans des conditions cardiovasculaires
EP3551202B1 (en)	2016-12-06	2024-01-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2018103868A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
MX2019006486A (es)	2016-12-09	2019-08-01	Zealand Pharma As	Agonistas duales acilados de glp-1/glp-2.
JP2020500890A (ja)	2016-12-09	2020-01-16	ジーランド・ファーマ・ア／エス	Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
GB201621987D0 (en)	2016-12-22	2017-02-08	Archer Virgil L See Archer Sheri A Arecor Ltd	Novel composition
MA49883A (fr)	2017-03-15	2021-04-21	Novo Nordisk As	Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2018210919A1 (en)	2017-05-17	2018-11-22	Novo Nordisk A/S	Glp-1 compositions and uses thereof
EP3630806B1 (en)	2017-05-31	2024-01-10	The University of Copenhagen	Long-acting gip peptide analogues
CA3082033A1 (en)	2017-08-24	2019-02-28	Novo Nordisk A\S	Glp-1 compositions and uses thereof
CN111163795A (zh)	2017-09-10	2020-05-15	诺沃挪第克公司	用于治疗肥胖症的mic-1和glp-1
EP3681900A4 (en)	2017-09-11	2021-09-08	Protagonist Therapeutics, Inc.	OPIOID AGONIST PEPTIDES AND THEIR USES
US20210261642A1 (en)	2017-12-19	2021-08-26	Novo Nordisk A/S	Solubility of glp-1 peptide
PE20210453A1 (es)	2018-02-02	2021-03-08	Novo Nordisk As	Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante
EP4501952A3 (en)	2018-02-08	2025-04-16	Protagonist Therapeutics, Inc.	Conjugated hepcidin mimetics
WO2019166411A1 (en)	2018-02-27	2019-09-06	Zealand Pharma A/S	Compstatin analogues and their medical uses
CN111936520A (zh)	2018-04-02	2020-11-13	百时美施贵宝公司	抗trem-1抗体及其用途
KR20250065720A (ko)	2018-04-05	2025-05-13	썬 파마슈티칼 인더스트리스 리미티드	신규한 glp-1 유사체
WO2019193204A1 (en)	2018-04-06	2019-10-10	Cyprumed Gmbh	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh)	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
WO2019209963A1 (en)	2018-04-24	2019-10-31	Deka Products Limited Partnership	Apparatus and system for fluid delivery
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2019222072A1 (en) *	2018-05-15	2019-11-21	Savior Lifetec Corporation	Preparation method of liraglutide derivative
US20210221867A1 (en)	2018-05-15	2021-07-22	Novo Nordisk A/S	Compounds Capable of Binding to Melanocortin 4 Receptor
US10905738B2 (en)	2018-07-05	2021-02-02	Biozeus Desenvolvimento De Produtos Biofarmacêuticos	Synthetic peptides, prodrugs, pharmaceutical compositions and uses
WO2020053414A1 (en)	2018-09-14	2020-03-19	Novo Nordisk A/S	Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
SG11202105586YA (en)	2018-12-03	2021-06-29	Antag Therapeutics Aps	Modified gip peptide analogues
WO2020187770A1 (en)	2019-03-15	2020-09-24	Diet4Life Aps	Combination of dietary peptides
JP2022527812A (ja)	2019-04-01	2022-06-06	ノヴォノルディスクアー／エス	リラグルチドに対する抗体およびその使用
JP7534382B2 (ja)	2019-07-10	2024-08-14	プロタゴニストセラピューティクス，インコーポレイテッド	インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
EP4021921A1 (en)	2019-08-27	2022-07-06	Zp Spv 3 K/S	Compstatin analogues and their medical uses
EP4025592A4 (en)	2019-09-03	2023-08-02	Protagonist Therapeutics, Inc.	CONJUGATED HEPCIDIN MIMETICS
BR112022007721A2 (pt)	2019-11-06	2022-07-12	Novo Nordisk As	Método para o tratamento da demência
WO2021089752A1 (en)	2019-11-07	2021-05-14	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (en)	2019-11-29	2021-06-03	Novo Nordisk A/S	Processes for obtaining stable glp-1 compositions
CN111040022B (zh)	2019-12-23	2021-12-14	万新医药科技(苏州)有限公司	针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
BR112022013042A2 (pt)	2019-12-30	2022-10-18	Gan & Lee Pharmaceuticals Co Ltd	Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
CN118005737A (zh)	2020-01-15	2024-05-10	詹森生物科技公司	介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
MX2022008740A (es)	2020-01-15	2022-09-23	Janssen Biotech Inc	Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
MX2022009844A (es)	2020-02-18	2022-09-05	Novo Nordisk As	Composiciones y usos del peptido similar al glucagon-1 (glp-1).
EP4126003A1 (en)	2020-03-30	2023-02-08	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
EP4126004A1 (en)	2020-03-30	2023-02-08	Zealand Pharma A/S	Agonist combination
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
WO2021219710A1 (en)	2020-04-29	2021-11-04	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist and histidine
EP4146221A1 (en)	2020-05-07	2023-03-15	Frederiksberg Hospital	Treatment of hyperuricemia
WO2022049310A1 (en)	2020-09-07	2022-03-10	Cyprumed Gmbh	Improved pharmaceutical formulations of glp-1 receptor agonists
WO2022068920A1 (en)	2020-09-30	2022-04-07	Beijing Ql Biopharmaceutical Co., Ltd.	Polypeptide conjugates and methods of uses
TW202237167A (zh)	2020-11-20	2022-10-01	比利時商健生藥品公司	介白素-23受體之肽抑制劑組合物
BR112023012422A2 (pt)	2021-01-24	2023-12-12	Michael David Forrest	Inibidores da atp sintase - usos cosmético e terapêutico
FR3120189B1 (fr)	2021-03-01	2024-11-29	Farid Bennis	Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
CN113025675B (zh) *	2021-05-21	2021-08-20	凯莱英医药集团（天津）股份有限公司	多肽的制备方法
WO2023285334A1 (en)	2021-07-12	2023-01-19	Novo Nordisk A/S	Novel fatty acid modified urocortin 2 derivatives and the uses thereof
CN116635402B (zh)	2021-07-14	2024-03-15	北京质肽生物医药科技有限公司	用于代谢病症的融合多肽
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
KR20240058121A (ko)	2021-09-03	2024-05-03	질랜드 파마 에이/에스	투여 용법
CA3231153A1 (en)	2021-09-08	2023-03-16	Kosuke Takemoto	Medicine for prevention and treatment of diseases linked to anti-obesity activity
JP2025511189A (ja) *	2022-03-28	2025-04-15	ブリストル－マイヤーズスクイブカンパニー	大環状免疫調節剤
IL319599A (en)	2022-09-19	2025-05-01	Zealand Pharma As	Combination therapy
TW202421654A (zh)	2022-09-28	2024-06-01	丹麥商西蘭製藥公司	治療肥胖之方法
EP4345104B1 (en)	2022-09-30	2024-08-28	Bachem Holding AG	Method for preparing liraglutide
WO2024110614A1 (en)	2022-11-25	2024-05-30	Novo Nordisk A/S	Oral administration of peptide therapeutics, such as glp-1
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases
WO2024141760A1 (en)	2022-12-30	2024-07-04	Algipharma As	Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2024252367A2 (en)	2023-06-09	2024-12-12	Sun Pharmaceutical Industries Limited	Novel glp-1/gip dual and glp-1/gcg dual receptor agonists
WO2024256632A1 (en)	2023-06-15	2024-12-19	Novo Nordisk A/S	Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
TW202515598A (zh)	2023-06-21	2025-04-16	丹麥商西蘭製藥公司	具有增進性能之類似物
TW202504913A (zh)	2023-06-21	2025-02-01	丹麥商西蘭製藥公司	減重
WO2025003471A1 (en)	2023-06-30	2025-01-02	Zealand Pharma A/S	Combination therapy
WO2025069009A1 (en)	2023-09-29	2025-04-03	Graviton Bioscience Bv	Rock2 inhibitors in the treatment of obesity
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4518586A (en) *	1983-01-13	1985-05-21	The Salk Institute For Biological Studies	GRF Analogs III
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
EP0305387B2 (en)	1986-05-05	1996-08-28	The General Hospital Corporation	Insulinotropic hormone
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
DK0512042T3 (da) *	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
EP0658568A1 (en) *	1993-12-09	1995-06-21	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
DK144093D0 (no) *	1993-12-23	1993-12-23	Novo Nordisk As
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE59510951D1 (de) *	1994-10-21	2004-11-11	Nutrinova Gmbh	Verfahren zur Kultivierung lipidabhängiger Tetrahymeniden und ein Verfahren zur Herstellung von biogenen Wertstoffen aus lipidabhängigen Tetrahymeniden
ATE356830T1 (de) *	1996-08-30	2007-04-15	Novo Nordisk As	Glp-1 derivate

1997
- 1997-08-22 AT AT97935509T patent/ATE356830T1/de active
- 1997-08-22 CZ CZ0062999A patent/CZ300837B6/cs not_active IP Right Cessation
- 1997-08-22 JP JP51118398A patent/JP3149958B2/ja not_active Expired - Lifetime
- 1997-08-22 CA CA2468374A patent/CA2468374C/en not_active Expired - Lifetime
- 1997-08-22 PL PL331896A patent/PL192359B1/pl unknown
- 1997-08-22 HU HU9903714A patent/HU227021B1/hu active Protection Beyond IP Right Term
- 1997-08-22 IL IL12833297A patent/IL128332A0/xx active IP Right Grant
- 1997-08-22 DE DE69737479A patent/DE69737479D1/de not_active Expired - Lifetime
- 1997-08-22 BR BRPI9711437A patent/BRPI9711437B8/pt not_active IP Right Cessation
- 1997-08-22 CA CA002264243A patent/CA2264243C/en not_active Expired - Lifetime
- 1997-08-22 CN CNB971984131A patent/CN1271086C/zh not_active Expired - Lifetime
- 1997-08-22 EP EP97935509A patent/EP0944648B1/en not_active Expired - Lifetime
- 1997-08-22 RU RU99106518/04A patent/RU2214419C2/ru active Protection Beyond IP Right Term
- 1997-08-22 UA UA99021142A patent/UA72181C2/uk unknown
- 1997-08-22 DE DE122009000079C patent/DE122009000079I2/de active Active
- 1997-08-22 WO PCT/DK1997/000340 patent/WO1998008871A1/en active Application Filing
- 1997-08-22 EP EP07103319A patent/EP1826216A1/en not_active Withdrawn
- 1997-08-22 KR KR1019997001750A patent/KR100556067B1/ko not_active Expired - Lifetime
- 1997-08-22 DE DE69737479T patent/DE69737479T4/de not_active Expired - Lifetime
- 1997-08-22 PT PT97935509T patent/PT944648E/pt unknown
- 1997-08-22 ES ES97935509T patent/ES2283025T3/es not_active Expired - Lifetime
- 1997-08-22 DK DK97935509T patent/DK0944648T3/da active
1999
- 1999-02-02 IL IL128332A patent/IL128332A/en active Protection Beyond IP Right Term
- 1999-02-26 NO NO19990950A patent/NO325273B1/no not_active IP Right Cessation
2000
- 2000-05-19 JP JP2000152778A patent/JP2001011095A/ja active Pending
2006
- 2006-07-24 JP JP2006201324A patent/JP2006348038A/ja active Pending
2008
- 2008-01-30 IL IL189136A patent/IL189136A/en not_active IP Right Cessation
2009
- 2009-10-22 NL NL300422C patent/NL300422I2/nl unknown
- 2009-10-23 FR FR09C0054C patent/FR09C0054I2/fr active Active
- 2009-11-18 NO NO2009027C patent/NO2009027I2/no unknown
2019
- 2019-09-20 NO NO2019036C patent/NO2019036I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NL300422I2 (nl)	2010-04-01
JP2006348038A (ja)	2006-12-28
CA2468374C (en)	2010-12-21
CA2468374A1 (en)	1998-03-05
HUP9903714A3 (en)	2000-07-28
NO990950L (no)	1999-04-28
IL128332A (en)	2008-04-13
CZ300837B6 (cs)	2009-08-26
DE122009000079I1 (de)	2010-05-27
DE122009000079I2 (de)	2011-06-16
IL128332A0 (en)	2000-01-31
EP0944648B1 (en)	2007-03-14
JP2001011095A (ja)	2001-01-16
NO2019036I1 (no)	2019-09-20
AU3847897A (en)	1998-03-19
DE69737479D1 (de)	2007-04-26
DE69737479T2 (de)	2007-11-29
NO2009027I2 (no)	2015-01-19
ES2283025T3 (es)	2007-10-16
DE69737479T4 (de)	2010-05-06
CN1271086C (zh)	2006-08-23
BR9711437A (pt)	2000-01-18
NO325273B1 (no)	2008-03-17
EP1826216A1 (en)	2007-08-29
BRPI9711437B1 (pt)	2017-05-16
PL192359B1 (pl)	2006-10-31
CA2264243A1 (en)	1998-03-05
CA2264243C (en)	2004-10-05
CZ62999A3 (cs)	1999-07-14
NL300422I1 (nl)	2010-01-04
AU732957C (en)	1998-03-19
IL189136A0 (en)	2008-06-05
KR20000035964A (ko)	2000-06-26
NO990950D0 (no)	1999-02-26
IL189136A (en)	2015-05-31
CN1232470A (zh)	1999-10-20
JP3149958B2 (ja)	2001-03-26
FR09C0054I1 (no)	2009-04-12
HUP9903714A2 (hu)	2000-03-28
ATE356830T1 (de)	2007-04-15
KR100556067B1 (ko)	2006-03-07
BRPI9711437B8 (pt)	2021-05-25
HU227021B1 (en)	2010-05-28
RU2214419C2 (ru)	2003-10-20
EP0944648A1 (en)	1999-09-29
AU732957B2 (en)	2001-05-03
PL331896A1 (en)	1999-08-16
WO1998008871A1 (en)	1998-03-05
DK0944648T3 (da)	2007-07-02
JP2000500505A (ja)	2000-01-18
UA72181C2 (uk)	2005-02-15
PT944648E (pt)	2007-06-26
FR09C0054I2 (fr)	2011-04-01

Publication	Publication Date	Title
NO2019036I1 (no)	2019-09-20	Liraglutid - forlenget SPC
NO902658L (no)	1990-12-17	N-fenylpyrazolderivater, preparater og anvendelse derav.
ITMI931717A0 (it)	1993-07-30	Derivati (di)azacicloesanici e diazacicloeptanici
KR960703888A (ko)	1996-08-31	이소플라본 유도체 (isoflavone derivatives)
FI901988A0 (fi)	1990-04-20	Koncentrerad, glutaraldehyd och 1,2-benzisotiazolin-3-on innehaollande, vattenhaltig loesning och dess anvaendning.
NL1007004A1 (nl)	1998-06-23	Foutcorrectiemethode en inrichting.
EP0702695A4 (en)	1997-06-18	THE CLONING EXPRESSION AND USE OF -i (DORSALIN-1)
NO885725D0 (no)	1988-12-22	Sammenleggbar hagelenestol.
NL191529C (nl)	1995-09-04	Inklapbaar zit- en ligmeubel.
NO894594D0 (no)	1989-11-17	Farmasoeytiske sammensetninger omfattende labdan diterpenoid-derivater og pyrimido(6,1-a)isoquinolin-4-ono-derivater.
ITRM990508A0 (it)	1999-08-05	Nitrilossi derivati della (r) e (s)-carnitina.
IT8919113A0 (it)	1989-01-18	Sci bipattino ripiegabile.
MX24407A (es)	1993-10-01	(1)benzopirano(4,3-c)-pirazoles y procedimiento para su preparacion.
FR2721057B1 (fr)	1996-09-06	Chapiteau pliable et dépliable rapidement.
FR2677028B1 (fr)	1994-01-21	Nouveaux derives sterouides du pregna-4,9(11),17(20)-trien-3-one.
IT8864214V0 (it)	1988-02-02	Porta accendino accessorio promozionale abbigliamento casual e jenseria.
IT1303471B1 (it)	2000-11-06	Sedia trasformabile in scaletta.
SE9600802D0 (sv)	1996-03-01	Ihopfällbart ben och armstöd
DE69206585D1 (de)	1996-01-18	Kathodestrahlrohr und herstellungsverfahren.
BR7300831U (pt)	1994-11-29	Cadeira retrátil.
DK0906297T3 (da)	2004-06-28	1,2,4-Benzothiadiazinderivater, fremstilling og anvendelse deraf
DK1042291T3 (da)	2005-10-03	Arylsubstituerede pyridylalkan-, alken- og alkyncarboxamidderivater, der er nyttige som cytostatiske og immunosuppressive midler
IT8819959A0 (it)	1988-03-25	Derivati alcossibenzimidazolici farmacologicamente attivi eprocedimento di preparazione.
ITFI930095A0 (it)	1993-05-13	Ginocchiera con tutori collaterali.
FR2703712B3 (fr)	1995-06-09	Escalier autoréglable et escamotable.